0001104659-23-089074.txt : 20230809 0001104659-23-089074.hdr.sgml : 20230809 20230809070520 ACCESSION NUMBER: 0001104659-23-089074 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230808 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Other Events FILED AS OF DATE: 20230809 DATE AS OF CHANGE: 20230809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MedTech Acquisition Corp CENTRAL INDEX KEY: 0001826667 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 853009869 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39813 FILM NUMBER: 231153325 BUSINESS ADDRESS: STREET 1: 48 MAPLE AVENUE CITY: GREENWICH STATE: CT ZIP: 06830 BUSINESS PHONE: 6462096063 MAIL ADDRESS: STREET 1: 48 MAPLE AVENUE CITY: GREENWICH STATE: CT ZIP: 06830 8-K 1 tm2323269d1_8k.htm FORM 8-K
0001826667 false 0001826667 2023-08-08 2023-08-08 0001826667 MTAC:UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember 2023-08-08 2023-08-08 0001826667 us-gaap:CommonClassAMember 2023-08-08 2023-08-08 0001826667 us-gaap:WarrantMember 2023-08-08 2023-08-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 8, 2023

 

MedTech Acquisition Corporation

(Exact name of registrant as specified in its charter)

 

Delaware   001-39813   85-3009869
(State or other jurisdiction of
incorporation)		   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

48 Maple Avenue,
Greenwich, CT		   06830
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 391-1288

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each
exchange on
which registered
Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant   MTACU   The Nasdaq Stock Market LLC
Class A common stock, par value $0.0001 per share   MTAC   The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share   MTACW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ 

 

 

 

 

 

 

  

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On August 8, 2023, MedTech Acquisition Corporation (the “Company”) held a special meeting of its stockholders (the “Special Meeting”), at which holders of 7,154,021 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”) (consisting of 7,154,020 shares of Class A Common Stock and 1 share of Class B Common Stock) were present in person or by proxy, representing 96.7% of the voting power of the Company’s Common Stock as of July 3, 2023 (the record date for the Special Meeting), and constituting a quorum for the transaction of business. The proposals listed below (individually a “Proposal” and, collectively, the “Proposals”) are described in more detail in the Company’s definitive proxy statement/prospectus (the “Proxy Statement”), which was filed with the U.S. Securities and Exchange Commission (the “SEC”) and mailed to stockholders on July 18, 2023.  Capitalized terms used in this Current Report on Form 8-K but not otherwise defined herein have the meanings ascribed to such terms in the Proxy Statement.

 

Each Proposal voted upon at the Special Meeting was approved and the final voting results are indicated below. The final voting results for each Proposal were as follows:

 

1. The Business Combination Proposal:

 

For   Against   Abstain
7,135,003   19,016   2

 

2. The Charter Approval Proposal:

 

i.Class A Common Stock 
For   Against   Abstain
7,135,004   19,016   0

 

ii.Class B Common Stock 
For   Against   Abstain
1   0   0

 

iii.Total Common Stock 
For   Against   Abstain
7,135,005   19,016   0

 

3A. Governance Proposal 3A:

 

For   Against   Abstain
7,134,005   20,016   0

 

3B. Governance Proposal 3B:

 

For   Against   Abstain
7,135,005   19,016   0

 

 

 

 

3C. Governance Proposal 3C:

 

For   Against   Abstain
7,135,005   19,016   0

 

3D. Governance Proposal 3D:

 

For   Against   Abstain
7,135,005   19,016   0

  

3E. Governance Proposal 3E:

 

For   Against   Abstain
7,135,005   19,016   0

 

4. The Stock Plan Proposal:

 

For   Against   Abstain
7,135,000   19,021   0

 

5. The ESPP Proposal:

 

For   Against   Abstain
7,135,000   19,021   0

 

6. The Nasdaq Proposal:

 

For   Against   Abstain
7,135,005   19,016   0

 

7A. Director Nomination Proposal A:

 

  i. Anil Singhal

 

For   Withheld
7,135,005   19,016

 

  ii. Kerry Hicks

 

For   Withheld
7,135,005   19,016

 

  iii. Sean Murphy

 

For   Withheld
7,135,005   19,016

 

  iv. David Matlin

 

For   Withheld
7,135,005   19,016

 

  v. Mats Wahlström

 

For   Withheld
7,135,005   19,016

 

  vi. Andrew von Eschenbach

 

For   Withheld
7,135,005   19,016

 

 

 

  vii. Mary Szela

 

For   Withheld
7,135,005   19,016

  

  viii. Arjun Desai

 

For   Withheld
7,135,005   19,016

  

  ix. George Kelly Martin

 

For   Withheld
7,135,005   19,016

 

7B. Director Nomination Proposal B:

 

  i. David J. Matlin

 

For   Withheld
7,135,005   19,016

 

  ii. David L. Treadwell

 

For   Withheld
7,135,005   19,016

 

  iii. Christopher C. Dewey

 

For   Withheld
7,135,005   19,016

 

As there were sufficient votes to approve each of the above proposals, the “Adjournment Proposal” described in the Proxy Statement was not presented to stockholders.

 

Item 8.01 Other Events.

 

As described in the Proxy Statement, the Company provided holders of its shares of Class A Common Stock with the opportunity to have all or a portion of their shares redeemed for cash upon the closing of the Business Combination. In connection with the Special Meeting, holders of an aggregate of 890,499 shares of Class A Common Stock elected to exercise their right to redeem their shares for a pro rata portion of the funds in the Company’s trust account (the “Trust Account”). As a result, assuming the completion of the Business Combination, approximately $9.42 million (approximately $10.58 per redeemed share) will be removed from the Trust Account to pay such holders.

 

Based on the results of the Special Meeting, the Business Combination and the related transactions are expected to be consummated subject to the satisfaction or waiver of the closing conditions as described in the Proxy Statement. Following the consummation of the Business Combination, the common stock and warrants of the Combined Company are expected to begin trading on the Nasdaq Global Market under the symbols “TLSI” and “TLSIW,” respectively. 

 

 Forward-Looking Statements

 

This Current Report on Form 8-K contains certain “forward-looking statements” within the meaning of the United States federal securities laws regarding the Company’s or TriSalus’ expectations, hopes, beliefs, assumptions, intentions or strategies regarding the future including, without limitation, statements regarding the anticipated timing of the completion of the Business Combination, the benefits of the proposed Business Combination, and the listing of the Combined Company’s securities on the Nasdaq Stock Market. These forward-looking statements generally are identified by words such as “intend,” “may,” “plan,” “will” and similar expressions or the negative or other variations of such statements. These statements are predictions, projections and other statements about future events that are based on various assumptions, whether or not identified in this Current Report on Form 8-K and on the current expectations of the Company’s and TriSalus’ respective managements and are not predictions of actual performance and, as a result, are subject to risks and uncertainties.

 

 

 

 

Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: (i) the risk that the Business Combination may not be completed in a timely manner or at all, which may adversely affect the price of the Company’s securities; (ii) the risk that the Business Combination may not be completed by the Company’s business combination deadline; (iii) the failure to satisfy the conditions to the consummation of the Business Combination, including the satisfaction of the minimum cash amount following any redemptions by the Company’s public stockholders and the receipt of certain governmental and regulatory approvals; (iv) the lack of a third-party valuation in determining whether or not to pursue the Business Combination on the terms set forth in the Merger Agreement; (v) the failure to satisfy the conditions to the consummation of the private placement of a to-be-authorized class of preferred stock, par value $0.0001 per share, that will be designated as Series A Convertible Stock to close concurrently with the Business Combination and the resulting impact on the amount of capital available to the Company at the potential closing of the Business Combination; (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (vii) the receipt of an unsolicited offer from another party for an alternative transaction that could interfere with the Business Combination; (viii) the effect of the announcement or pendency of the Business Combination on TriSalus’ business relationships, operating results and business generally; (ix) the risk that the Business Combination disrupts current plans and operations of TriSalus; (x) the outcome of any legal proceedings that may be instituted against TriSalus or the Company related to the Merger Agreement or the Business Combination; (xi) the ability to maintain the listing of the Company’s securities on the Nasdaq; (xii) changes in business, market, financial, political and legal conditions; (xiii) unfavorable changes in the reimbursement environment for TriSalus’ products; (xiv) the ability of the Company or the combined company to raise additional financing in connection with the Business Combination or to finance its operations in the future; (xv) the ability to implement business plans, forecasts and other expectations after the completion of the Business Combination, and identify and realize additional opportunities; (xvi) costs related to the Business Combination; (xvii) the failure to realize the anticipated benefits of the Business Combination or to realize estimated pro forma results and the underlying assumptions, including with respect to estimated stockholder redemptions; and (xviii) other risks and uncertainties indicated from time to time in the Registration Statement, including those under the “Risk Factors” section therein and in the Company’s other filings with the SEC. The foregoing list of factors is not exclusive.

 

The Company’s other SEC filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and none of the Company, TriSalus, or any of their respective representatives assume any obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. None of the Company, TriSalus, or any of their respective representatives gives any assurance that either the Company or TriSalus will achieve its expectations.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MedTech Acquisition Corporation
   
Dated: August 9, 2023 By: /s/ Christopher C. Dewey
    Name: Christopher C. Dewey
    Title: Chief Executive Officer

 

 

 

 

 EX-101.SCH 2 mtac-20230808.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 mtac-20230808_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 4 mtac-20230808_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant [Member] Common Class A [Member] Warrant [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Units, each consisting of one share of Class A Common Stock and one-third of one Redeemable Warrant EX-101.PRE 5 mtac-20230808_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 08, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 08, 2023
Entity File Number 001-39813
Entity Registrant Name MedTech Acquisition Corporation
Entity Central Index Key 0001826667
Entity Tax Identification Number 85-3009869
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 48 Maple Avenue
Entity Address, City or Town Greenwich
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06830
City Area Code 908
Local Phone Number 391-1288
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant
Trading Symbol MTACU
Security Exchange Name NASDAQ
Common Class A [Member]  
Document Information [Line Items]  
Title of 12(b) Security Class A common stock, par value $0.0001 per share
Trading Symbol MTAC
Security Exchange Name NASDAQ
Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share
Trading Symbol MTACW
Security Exchange Name NASDAQ
XML 7 tm2323269d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001826667 2023-08-08 2023-08-08 0001826667 MTAC:UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember 2023-08-08 2023-08-08 0001826667 us-gaap:CommonClassAMember 2023-08-08 2023-08-08 0001826667 us-gaap:WarrantMember 2023-08-08 2023-08-08 iso4217:USD shares iso4217:USD shares 0001826667 false 8-K 2023-08-08 MedTech Acquisition Corporation DE 001-39813 85-3009869 48 Maple Avenue Greenwich CT 06830 908 391-1288 true false false false Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant MTACU NASDAQ Class A common stock, par value $0.0001 per share MTAC NASDAQ Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share MTACW NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9 MNMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MT MFF6SU%L,9KD8M;:X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5 MRMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"% M'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:P MIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0 ( M *DX"5&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_ M[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ M0=@S9)[NF:*'3^ 5!+ P04 M " "I. E799!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RM MDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C> MO,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0 MP1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH% M.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D M(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S6 M3AI_YHOA/UY_ 5!+ 0(4 Q0 ( *DX"5<'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ J3@)5S60 M#"KO *P( !$ ( !KP &1O8U!R;W!S+V-O&UL M4$L! A0#% @ J3@)5YE&PO=V]R:W-H965T&UL M4$L! A0#% @ J3@)5Y^@&_"Q @ X@P T ( !S@T M 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! M A0#% @ J3@)5R0>FZ*M ^ $ !H ( !\Q( 'AL M+U]R96QS+W=O9(9 M 0 SP, !, ( !V!, %M#;VYT96YT7U1Y<&5S72YX;6Q0 52P4& D "0 ^ @ (A4 end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 4 23 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://medtechacquisitioncorp.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2323269d1_8k.htm mtac-20230808.xsd mtac-20230808_def.xml mtac-20230808_lab.xml mtac-20230808_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2323269d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 29 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "mtac-20230808_def.xml" ] }, "inline": { "local": [ "tm2323269d1_8k.htm" ] }, "labelLink": { "local": [ "mtac-20230808_lab.xml" ] }, "presentationLink": { "local": [ "mtac-20230808_pre.xml" ] }, "schema": { "local": [ "mtac-20230808.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 1, "memberStandard": 2, "nsprefix": "MTAC", "nsuri": "http://medtechacquisitioncorp.com/20230808", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2323269d1_8k.htm", "contextRef": "AsOf2023-08-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://medtechacquisitioncorp.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2323269d1_8k.htm", "contextRef": "AsOf2023-08-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "MTAC_UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Units, each consisting of one share of Class A Common Stock and one-third of one Redeemable Warrant", "label": "Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant [Member]" } } }, "localname": "UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember", "nsuri": "http://medtechacquisitioncorp.com/20230808", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001104659-23-089074-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-089074-xbrl.zip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end